Researchers have identified a library of molecules that shut down the SARS-CoV-2 polymerase reaction, a key step that establishes the potential of these molecules as lead compounds to be further modified for the development of COVID-19 therapeutics. Five of these molecules are already FDA-approved for use in the treatment of other viral infections including HIV/AIDS, cytomegalovirus, and hepatitis B.
Researchers identify multiple molecules that shut down SARS-Cov-2 polymerase reaction
- 30. 6 2020 (18:51)